GlassScriptPhysician profile
Sara Haile
NPI 1134309180
$1,497.34
in general payments reported to CMS, 2019-2025
20 companies · $575 in 2025
The $575 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $141 · 2022: $231 · 2023: $370 · 2024: $179 · 2025: $575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,124.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $484.90 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $248.01 | 2021-2025 | |
| Abbvie INC. | $133.83 | 2022-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $85.44 | 2025 | Caplyta |
| Exact Sciences Corporation | $76.83 | 2023-2025 | Cologuard Collection Kit |
| Davol INC. | $54.61 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $49.19 | 2025 | |
| Smith+Nephew, INC. | $47.44 | 2021-2025 | Renasys Go V2 Home |
| Glaxosmithkline, LLC. | $46.97 | 2024-2025 | Trelegy Ellipta |
| Biohaven Pharmaceutical Holding Company LTD. | $46.78 | 2022 | |
| Lundbeck LLC | $42.44 | 2024-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $40.45 | 2025 | |
| Corcept Therapeutics | $34.08 | 2025 | Korlym |
| Abbott Laboratories | $24.38 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.85 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $15.89 | 2023 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $15.62 | 2025 | Rexulti |
| Baxter Healthcare | $13.11 | 2023 | Floseal |
| Dynavax Technologies Corporation | $11.68 | 2023 | Heplisav-B |
| Phathom Pharmaceuticals, INC. | $8.84 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Haile listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.